PARProceedings of Anticancer Research2208-35452208-3553Bio-Byword Scientific Publishing Pty. Ltd.10.26689/par.v10i2.14539ArticleAcinar-to-Ductal Metaplasia in Chronic Pancreatitis: A Critical Link Between Inflammation and Pancreatic Carcinogenesishttps://artdesignp.com/journal/PAR/10/2/10.26689/par.v10i2.14539LinZhenyu,LuJie20261022026-04-14Chronic pancreatitis (CP) is a progressive fibroinflammatory disorder that results from the interplay of genetic, environmental, immune, and pathogenic factors. Traditionally characterized by irreversible pancreatic injury, CP is now recognized as an important precursor to pancreatic ductal adenocarcinoma (PDAC), a deadly form of pancreatic cancer. The persistent inflammatory microenvironment of CP promotes the accumulation of genetic mutations and cellular reprogramming, which can lead to acinar-to-ductal metaplasia (ADM), a precursor lesion of PDAC. ADM represents a reversible cellular reprogramming process, wherein pancreatic acinar cells transform into duct-like cells in response to inflammatory stress. This process is critical in both tissue repair and, under sustained inflammatory or oncogenic conditions, the progression to neoplasia. The molecular drivers of ADM include inflammatory cytokines, oxidative stress, extracellular matrix remodeling, and transcriptional reprogramming. Notably, the activation of signaling pathways such as Notch, EGFR/RAS/MAPK, and Wnt/β-catenin play pivotal roles in regulating ADM and its progression toward pancreatic cancer. Furthermore, the AKT/GSK3β signaling axis emerges as a central regulator in the modulation of ADM and its subsequent transition to malignancy. Understanding the molecular mechanisms of ADM and its interplay with pancreatic stellate cells provides valuable insights into therapeutic targets that could interrupt the progression from chronic pancreatitis to pancreatic cancer. This review highlights the pathophysiology of CP, the role of ADM in inflammation-driven pancreatic carcinogenesis, and the signaling networks involved in this process. By examining the regulatory pathways that govern ADM, this article aims to provide a framework for future therapeutic strategies that could target ADM and delay the progression of CP to PDAC. Early intervention in the ADM process, particularly in its reversible stages, presents a promising approach for preserving acinar cell function, preventing fibrosis, and ultimately reducing the risk of pancreatic cancer.

Thierens ND, Verdonk RC, Löhr JM, et al., 2025, Chronic Pancreatitis. Lancet, 404(10471): 2605–2618.

Vege SS, Chari ST, 2022, Chronic Pancreatitis. N Engl J Med, 386(9): 869–878.

Beyer G, Hoffmeister A, Lorenz P, et al., 2022, Clinical Practice Guideline—Acute and Chronic Pancreatitis. Dtsch Arztebl Int, 119(29–30): 495–501.

Ashraf H, Colombo JP, Marcucci V, et al., 2021, A Clinical Overview of Acute and Chronic Pancreatitis: The Medical and Surgical Management. Cureus, 13(11): e19764.

Wang D, Han S, Lv G, et al., 2025, Pancreatic Acinar Cells-Derived Sphingosine-1-Phosphate Contributes to Fibrosis of Chronic Pancreatitis Via Inducing Autophagy and Activation of Pancreatic Stellate Cells. J Cell Mol Med, 29(4): e70315.

An J, Jiang T, Qi L, et al., 2023, Acinar Cells and the Development of Pancreatic Fibrosis. Cytokine Growth Factor Rev, 71–72: 40–53.

Inamdar TV, Krannich F, Hesselbarth N, et al., 2025, Hereditary Chronic Pancreatitis Induced Plasticity Cooperates with Mutant Kras in Early Pancreatic Carcinogenesis. Gut, Advance Online Publication.

Marstrand-Daucé L, Lorenzo D, Chassac A, et al., 2023, Acinar-To-Ductal Metaplasia (ADM): On the Road to Pancreatic Intraepithelial Neoplasia (PanIN) and Pancreatic Cancer. Int J Mol Sci, 24(12): 9911.

Li S, Xie K, 2022, Ductal Metaplasia in Pancreas. Biochim Biophys Acta Rev Cancer, 1877(2): 188698.

Jiang J, Hakimjavadi H, Bray JK, et al., 2023, Transcriptional Profile of Human Pancreatic Acinar Ductal Metaplasia. Gastro Hep Adv, 2(4): 532–543.

Zhang Y, Zhang WQ, Liu XY, et al., 2023, Immune Cells and Immune Cell-Targeted Therapy In Chronic Pancreatitis. Front Oncol, 13: 1151103.

Xiang H, Yu H, Zhou Q, et al., 2022, Macrophages: A Rising Star in Immunotherapy for Chronic Pancreatitis. Pharmacol Res, 185: 106508.

Chung WC, Xu K, 2023, Notch Signaling Pathway in Pancreatic Tumorigenesis. Adv Cancer Res, 159: 1–36.

Neuß T, Chen MC, Wirges N, et al., 2024, Metabolic Reprogramming Is an Initial Step In Pancreatic Carcinogenesis That Can Be Targeted to Inhibit Acinar-To-Ductal Metaplasia. Cancer Res, 84(14): 2299–2313.

Napolitano T, Silvano S, Ayachi C, et al., 2023, Wnt Pathway in Pancreatic Development and Pathophysiology. Cells, 12(4): 565.

Al-Hetty HR, Abdulameer SJ, Alkubaisy SA, et al., 2023, STAT3 Signaling in Pancreatic Ductal Adenocarcinoma: A Candidate Therapeutic Target. Pathol Res Pract, 245: 154425.

Hamel Z, Sanchez S, Standing D, et al., 2024, Role of STAT3 In Pancreatic Cancer. Explor Target Antitumor Ther, 5(5): 20–34.

Campos AD, Shepard RM, Ortega Z, et al., 2025, A STAT3/Integrin Axis Accelerates Pancreatic Cancer Initiation and Progression. Cell Rep, 44(8): 116010.

Sastre J, Pérez S, Sabater L, et al., 2025, Redox Signaling in the Pancreas in Health and Disease. Physiol Rev, 105(2): 593–650.

Uddin MH, Zhang D, Muqbil I, et al., 2024, Deciphering Cellular Plasticity in Pancreatic Cancer for Effective Treatments. Cancer Metastasis Rev, 43(1): 393–408.

Lo EK, Idrizi A, Tryggvadottir R, et al., 2025, DNA Methylation Memory of Pancreatic Acinar-Ductal Metaplasia Transition State Altering Kras-Downstream PI3K And Rho GTPase Signaling in the Absence of Kras Mutation. Cell Rep, 44(4): 115589.

Kong F, Pan Y, Wu D, 2024, Activation and Regulation of Pancreatic Stellate Cells in Chronic Pancreatic Fibrosis: A Potential Therapeutic Approach for Chronic Pancreatitis. Biomedicines, 12(1): 108.

Wang Z, Dong S, Zhou W, 2024, Pancreatic Stellate Cells: Key Players in Pancreatic Health and Diseases (Review). Mol Med Rep, 30(1): 109.

Huang H, Lu W, Zhang X, et al., 2024, Fibroblast Subtypes in Pancreatic Cancer and Pancreatitis: From Mechanisms to Therapeutic Strategies. Cell Oncol (Dordr), 47(2): 383–396.

Hu C, Yin L, Chen Z, et al., 2021, The Unique Pancreatic Stellate Cell Gene Expression Signatures Are Associated with the Progression from Acute to Chronic Pancreatitis. Comput Struct Biotechnol J, 19: 5791–5799.

Han D, Wen C, Li J, et al., 2024, Pancreatic Stellate Cells Promote Pancreatic Regeneration in Chronic Pancreatitis Via Exosomal LncRNA MALAT1-Induced Acinar-Ductal Metaplasia. Biochem Biophys Res Commun, 723: 150248.

Li H, Liu D, Li K, et al., 2024, Pancreatic Stellate Cells and the Interleukin Family: Linking Fibrosis and Immunity to Pancreatic Ductal Adenocarcinoma (Review). Mol Med Rep, 30(3): 159.

Sun L, Zheng M, Gao Y, et al., 2024, Retinoic Acid Signaling Pathway In Pancreatic Stellate Cells: Insight into the Anti-Fibrotic Effect and Mechanism. Eur J Pharmacol, 967: 176374.

Iyer S, Enman M, Sahay P, et al., 2024, Novel Therapeutics to Treat Chronic Pancreatitis: Targeting Pancreatic Stellate Cells and Macrophages. Expert Rev Gastroenterol Hepatol, 18(4–5): 171–183.

Halbrook CJ, Lyssiotis CA, Pasca M, et al., 2023, Pancreatic Cancer: Advances and Challenges. Cell, 186(8): 1729–1754.